2025 Q4 -tulosraportti
65 päivää sitten
‧1 t 12 min
0,8737 USD/osake
Viimeisin osinko
3,29%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sitten
·3.4.Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA in early 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication containing orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients taking weight loss medication with orforglipron. The Danish pharmaceutical company states this in a press release. The American drug agency, FDA, approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron, on Wednesday. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA in early 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. home NEWS Read also: Apartments evacuated after partial gable collapse The obesity conference is held from April 10 to 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substance semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. a jawbone NEWS Read also: Archaeologists vacuumed Danish ship and found human jawbone Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. According to the media outlet MarketWire, the pill will be launched at a price of 149 dollar per month for the lowest dose for self-paying individuals. Americans covered by the public health insurance Medicare can get the pill for 50 dollar per month. Novo Nordisk's pill also costs 149 dollar per month for self-paying users. From August 31, the price will increase to 199 dollar per month. For individuals covered by health insurance, the price starts at 25 dollar per month, according to MarketWire. /ritzau/- ·19.3.Novo gets green light for new obesity drug in USA Novo Nordisk has had a new, higher-dosed version of its obesity drug Wegovy approved in the USA. Chief Financial Officer (CFO) Karsten Munk Knudsen and Novo Nordisk's Chief Executive Officer (CEO) Mike Doustdar. Chief Financial Officer (CFO) Karsten Munk Knudsen and Novo Nordisk's Chief Executive Officer (CEO) Mike Doustdar. Archive photo:Thomas Traasdahl/Ritzau Scanpix MAYA ANASTASIA LARSEN 19. MAR. 2026 AT 16.45 The American pharmaceutical authority U.S. Food and Drug Administration (FDA) has approved Wegovy HD (semaglutide 7.2 mg), which in clinical studies has shown an average weight loss of 20.7 pct. Approximately every third patient achieved a weight loss of at least 25 pct.
·27.3.There we have yet another explanation for the price development ... the stock market is controlled by Big money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
65 päivää sitten
‧1 t 12 min
0,8737 USD/osake
Viimeisin osinko
3,29%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten
- ·3.4.Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA in early 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication containing orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients taking weight loss medication with orforglipron. The Danish pharmaceutical company states this in a press release. The American drug agency, FDA, approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron, on Wednesday. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA in early 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. home NEWS Read also: Apartments evacuated after partial gable collapse The obesity conference is held from April 10 to 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substance semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. a jawbone NEWS Read also: Archaeologists vacuumed Danish ship and found human jawbone Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. According to the media outlet MarketWire, the pill will be launched at a price of 149 dollar per month for the lowest dose for self-paying individuals. Americans covered by the public health insurance Medicare can get the pill for 50 dollar per month. Novo Nordisk's pill also costs 149 dollar per month for self-paying users. From August 31, the price will increase to 199 dollar per month. For individuals covered by health insurance, the price starts at 25 dollar per month, according to MarketWire. /ritzau/
- ·19.3.Novo gets green light for new obesity drug in USA Novo Nordisk has had a new, higher-dosed version of its obesity drug Wegovy approved in the USA. Chief Financial Officer (CFO) Karsten Munk Knudsen and Novo Nordisk's Chief Executive Officer (CEO) Mike Doustdar. Chief Financial Officer (CFO) Karsten Munk Knudsen and Novo Nordisk's Chief Executive Officer (CEO) Mike Doustdar. Archive photo:Thomas Traasdahl/Ritzau Scanpix MAYA ANASTASIA LARSEN 19. MAR. 2026 AT 16.45 The American pharmaceutical authority U.S. Food and Drug Administration (FDA) has approved Wegovy HD (semaglutide 7.2 mg), which in clinical studies has shown an average weight loss of 20.7 pct. Approximately every third patient achieved a weight loss of at least 25 pct.·27.3.There we have yet another explanation for the price development ... the stock market is controlled by Big money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
65 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
0,8737 USD/osake
Viimeisin osinko
3,29%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sitten
- ·3.4.Wegovy pill beats competitor in new Novo Nordisk studies Novo Nordisk's Wegovy pill was launched in the USA in early 2026. (Archive photo). (Photo: Søren Bidstrup/Ritzau Scanpix) Wegovy pill provides three percentage points greater weight loss than weight loss medication containing orforglipron. Ritzau April 2, 2026 15:58 According to new studies from Novo Nordisk, patients on Wegovy pills achieved a weight loss of 3.0 to 3.2 percentage points greater than in patients taking weight loss medication with orforglipron. The Danish pharmaceutical company states this in a press release. The American drug agency, FDA, approved Eli Lilly's weight loss pill Foundayo, which contains orforglipron, on Wednesday. Foundayo is in direct competition with Novo Nordisk's Wegovy pill, which was launched in the USA in early 2026. Novo Nordisk's results will be presented at the annual obesity conference Obesity Medicine, the Danish pharmaceutical company states. home NEWS Read also: Apartments evacuated after partial gable collapse The obesity conference is held from April 10 to 12 in the American state of California by the Obesity Medicine Association, an organization of doctors, nurses, and other healthcare professionals who work with the treatment of severe obesity. Both the substance semaglutide and orforglipron belong to the group of GLP-1 receptors. GLP-1 is a hormone that lowers blood sugar and inhibits appetite. According to the Danish Medicines Agency, headache, nausea, vomiting, diarrhea, constipation, abdominal pain, and fatigue are among the most common side effects of Wegovy, among others. According to Novo Nordisk's studies, there is a greater likelihood of stopping treatment with orforglipron due to side effects compared to the Wegovy pill with semaglutide. a jawbone NEWS Read also: Archaeologists vacuumed Danish ship and found human jawbone Eli Lilly's pill will be available for shipment from April 6 through LillyDirect, where the drug is delivered directly to users bypassing traditional pharmacies. According to the media outlet MarketWire, the pill will be launched at a price of 149 dollar per month for the lowest dose for self-paying individuals. Americans covered by the public health insurance Medicare can get the pill for 50 dollar per month. Novo Nordisk's pill also costs 149 dollar per month for self-paying users. From August 31, the price will increase to 199 dollar per month. For individuals covered by health insurance, the price starts at 25 dollar per month, according to MarketWire. /ritzau/
- ·19.3.Novo gets green light for new obesity drug in USA Novo Nordisk has had a new, higher-dosed version of its obesity drug Wegovy approved in the USA. Chief Financial Officer (CFO) Karsten Munk Knudsen and Novo Nordisk's Chief Executive Officer (CEO) Mike Doustdar. Chief Financial Officer (CFO) Karsten Munk Knudsen and Novo Nordisk's Chief Executive Officer (CEO) Mike Doustdar. Archive photo:Thomas Traasdahl/Ritzau Scanpix MAYA ANASTASIA LARSEN 19. MAR. 2026 AT 16.45 The American pharmaceutical authority U.S. Food and Drug Administration (FDA) has approved Wegovy HD (semaglutide 7.2 mg), which in clinical studies has shown an average weight loss of 20.7 pct. Approximately every third patient achieved a weight loss of at least 25 pct.·27.3.There we have yet another explanation for the price development ... the stock market is controlled by Big money
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt